Navigating Interdisciplinary Care for Tumor-Infiltrating Lymphocyte Therapy in Melanoma

Author(s)Rebekah R. Dyer, PharmD, BCPS

Lifileucel treats advanced melanoma by harvesting, expanding, and reinfusing a patient's own tumor-infiltrating immune cells.

Tumor-infiltrating lymphocyte (TIL) immunotherapy is a cellular treatment that utilizes a patient’s immune cells to fight and kill cancer cells. Approved by the FDA in 2024, lifileucel (Amtagvi; Iovance Biotherapeutics, Inc) is the first autologous cellular therapy approved for a cancerous solid tumor, specifically in adult patients with unresectable or metastatic melanoma.